Status:
COMPLETED
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
Lead Sponsor:
GE Healthcare
Conditions:
Congestive Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 mo...
Eligibility Criteria
Inclusion
- The subject was a Heart Failure subject who signed informed consent for MBG311, MBG312, or MBG312C.
- The subject was administered 123I-mIBG in MBG311, MBG312, or MBG312C.
- The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311, MBG312, or MBG312C.
- The subject agreed to allow the investigator access to medical records, including those relating to subject death should this occur.
Exclusion
- The subject withdrew or was withdrawn from MBG311, MBG312, or MBG312C.
- The subject was considered lost-to-follow-up (6 months without contact) in MBG311, MBG312, or MBG312C.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
471 Patients enrolled
Trial Details
Trial ID
NCT00785044
Start Date
May 1 2008
End Date
February 1 2010
Last Update
April 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GE Healthcare
Princeton, New Jersey, United States, 08540